BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Colorcon
Citi
Mallinckrodt
Healthtrust
Cantor Fitzgerald
Express Scripts
Argus Health
Queensland Health
Fuji

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204399

« Back to Dashboard

NDA 204399 describes VOGELXO, which is a drug marketed by Upsher-smith Labs and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug. Additional details are available on the VOGELXO profile page.

The generic ingredient in VOGELXO is testosterone. There are sixty-two drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the testosterone profile page.
Summary for 204399
Tradename:VOGELXO
Applicant:Upsher-smith Labs
Ingredient:testosterone
Patents:3
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers)
Formulation / Manufacturing:see details
Pharmacology for NDA: 204399
Ingredient-typeAndrostanes
Mechanism of ActionAndrogen Receptor Agonists
Medical Subject Heading (MeSH) Categories for 204399
Suppliers and Packaging for NDA: 204399
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VOGELXO testosterone GEL, METERED;TRANSDERMAL 204399 NDA Upsher-Smith Laboratories, LLC 0245-0871 0245-0871-05 30 TUBE in 1 CARTON (0245-0871-05) > 5 g in 1 TUBE (0245-0871-65)
VOGELXO testosterone GEL;TRANSDERMAL 204399 NDA Upsher-Smith Laboratories, LLC 0245-0871 0245-0871-05 30 TUBE in 1 CARTON (0245-0871-05) > 5 g in 1 TUBE (0245-0871-65)

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:GEL;TRANSDERMALStrength50MG/5GM PACKET
Approval Date:Jun 4, 2014TE:AB2RLD:No
Regulatory Exclusivity Expiration:Jun 4, 2017
Regulatory Exclusivity Use:NEW PRODUCT
Patent:➤ SubscribePatent Expiration:Feb 11, 2034Product Flag?YSubstance Flag?Delist Request?
Patented Use:METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE
Patent:➤ SubscribePatent Expiration:Feb 11, 2034Product Flag?YSubstance Flag?Delist Request?
Patented Use:METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Argus Health
Farmers Insurance
Citi
AstraZeneca
Accenture
Boehringer Ingelheim
Johnson and Johnson
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot